Document detail

6 June 2022 These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. This document has been updated: Version 6 June 2022.

vaccine,  johnson&Johnson,  recommendations,  approval,  COVID-19,  SARS-CoV-2,  vector-basierter Impfstoff,